Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib rechallenge maintenance in platinum-sensitive first recurrent ovarian cancer
ChiCTR2200058613Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Renji Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200058613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058613.